tqb2102
Non-Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Phase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 59/ 100
Competitive context
175 Active assets in the Non-Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Anamorelin Helsinn Healthcare SA | Phase 3 | BB |
ETOPOSIDE Pfizer | Phase 3 | BB |
Atezolizumab National Cancer Institute (NCI) | Phase 4 | BB |
Docetaxel Genfleet Therapeutics (Shanghai) Inc. | Phase 4 | BB |
Panobinostat Pfizer | Phase 4 | BB |
View all 50 →
Same molecule, other indications
tqb2102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →